GSK, J&J tout Cabenuva preference over Gilead's Biktarvy
Nadzeya Haroshka/iStock via Getty Images

ViiV Healthcare, which is majority owned by GSK (NYSE:GSK), and Johnson & Johnson (NYSE:JNJ) say phase 3 study data indicates that patients prefer the long-acting HIV injectable medicine Cabenuva over Gilead Sciences' (NASDAQ:GILD) daily pill Biktarvy.
Results from the SOLAR switching study, sponsored by ViiV, found that 90% of participants preferred Cabenuva over Biktarvy.

Cabenuva can be dosed monthly or every two months.
In the trial, which lasted a year, 447 patients started on Biktarvy (bictegravir/emtricitabine/tenofovir) and then switched to Cabenuva (cabotegravir/rilpivirine). Another 223 were always on Biktarvy.
Results also found that those who switched to Cabenuva saw greater improvements in fear of disclosure, anxiety relating to adherence requirements, and daily reminder of their HIV status compared to those who were on Biktarvy throughout the trial.

More on HIV treatments

GSK's long-acting HIV med Cabenuva equals Gilead's daily Biktarvy
Gilead HIV drug Biktarvy shows sustained efficacy in long term data
GSK: A Biopharma Giant On Sale
Gilead Sciences: An Evolving Biopharma Navigating Through Challenges And Opportunities